Media.Player

High Throughput Label-Free One-Bead-One-Compound (OBOC) Screening Assay

技術優勢

Produces label-free assay for screening Produces true sense of binding through elimination of false-positive interactions

技術應用

Label-free screening assay

詳細技術說明

Traditional OBOC screening assays are currently performed by attaching a fluorescent or enzyme based label on a target to determine its binding to a library of test compounds. OBOC libraries have been used to identify a nearly limitless number of macromolecule-binding compounds, including compounds that are useful against cancers. While current methods of OBOC screening have successfully detected new synthetic compounds or ligands, these methods have several shortcomings. Specifically: (i) the attachment of a label can interfere with binding, (ii) the label may sterically inhibit parts of the target macromolecule and (iii) the process of attaching a label can alter the structure of the target macromolecule. Researchers at the University of California, Davis have developed a high throughput, label-free OBOC screening assay. Compared to current methods, this assay discriminates between beads that bind to the target by staining target molecules directly with either silver or fluorescent stains. After target binding, the beads are then gelled and pulled off the target through electrophoresis. The target molecules migrate a short distance from their bounded bead and appear as a ‘comet’ or streak of staining within the gel. This unique combination of staining and electrophoresis provides previously unknown benefits for OBOC screening.

*Abstract

Researchers at the University of California, Davis have developed a high throughput, label-free One-Bead-One-Compound (OBOC) screening assay.

*IP Issue Date

Oct 27, 2016

*Principal Investigation

Name: Kit Lam

Department:

Name: Michael Schlein

Department:

申請號碼

20160313311

其他

Additional Technologies by these Inventors

• Ligands for Alpha-4-Beta-1 Integrin
• Three-Dimensional Cell Adhesion Matrix
• A Novel RGD-Containing Cyclic Peptide for use in Cancer Imaging and as a Targeted-Therapy Ligand
• Functional Illumination in Living Cells
• Nanoparticles for Drug Delivery, Tissue Targeting and Imaging Analysis
• Nanoporphyrin Nanoparticles for Combination Phototherapy and Drug Delivery to Infantile Hemangiomas
• Early Detection of Ovarian Cancer Using Markers to Short Chain Carbohydrates
• PVA Nanocarrier System for Controlled Drug Delivery
• Site-Specific Ligation and Compound Conjugation to Existing Antibodies
• Novel Solid Tumor Chemodrug LLS2
• Ligands for Improved Angiogenesis and Endothelialization of Blood Contacting Devices
• Proteoglycan Mimetics For Enhanced Wound Healing Angiogenesis And Vascular Repair

Tech ID/UC Case

27247/2014-564-0

Related Cases

2014-564-0

國家/地區

美國